Skip to main content

Table 4 Comparison between the 21st Nationwide survey and the second cohort

From: Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study

  21st Nationwide survey n; % Second cohort group n; % p-value Odds ratio 95% CI
Total 23,730; 100.0 112; 100.0   (crude)  
Initial IVIG therapy 21,247; 89.5 104; 92.9 0.24 0.46 0.23–0.95
    0.31* 1.20* 0.86–1.69*
Acute phase CAL 2,044; 8.6 3; 2.7 0.03 3.43 1.09–10.79
Cardiac sequelae 696; 2.9 1; 0.9 0.32 3.35 0.47–24.06
Additional IVIG therapy 4,049; 17.1 10; 8.9 0.02 2.10 1.10–4.02
Resistance for IVIG therapy 3,532; 14.9 4; 3.6 < 0.001 5.16 1.09–14.00
  1. *Adjusted odds ratio for dosage of initial IVIG therapy in both groups was obtained using the Mantel-Haenstzel method adjusted for various initial dosages of intravenous immunoglobulin (2 g/kg, 1 g/kg, 400 mg/kg, or various dosages of IVIG). Adjusted odds ratio for acute-phase CAL, cardiac sequelae, and additional IVIG therapy were not analyzed because there were no descriptions of dosages of various initial IVIG in the nationwide surveys.